Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-9202
- Development stage
- Preclinical
- Lead developer
- Beta Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BPI-9202 is a bispecific monoclonal antibody being developed by Beta Pharma. It is designed to simultaneously target two key immune checkpoint pathways: CD47 (Cluster of Differentiation 47) and PD-L1 (Programmed Death-Ligand 1). CD47 is a 'don't eat me' signal expressed on the surface of many cancer cells that inhibits phagocytosis by macrophages, while PD-L1 is a ligand that suppresses T-cell activation by binding to the PD-1 receptor. By dual-targeting these proteins, BPI-9202 aims to synergistically enhance both innate and adaptive anti-tumor immune responses. The drug is currently in early-stage development for the treatment of solid tumors.
- Other names
- BPI-9202-Beta Pharma-CD47-PD-L1-monoclonal antibodyBPI9202-Beta Pharma-CD47-PD-L1-monoclonal antibodyBPI 9202-Beta Pharma-CD47-PD-L1-monoclonal antibody
02
Targets
CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on BPI-9202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI-9202.